LAKE FOREST, CA--(Marketwire - August 18, 2008) - TRIMEDYNE, INC. (OTCBB: TMED) today announced it has entered into a Letter of Intent with FemSuite, LLC, a privately held company based in San Francisco which develops, manufactures and markets a variety of devices for use in the gynecology field. Under the Letter of Intent, Trimedyne has offered to license seven of its U.S. patents and two U.S. patent applications (the "Patents") exclusively to FemSuite for any use in the fields of Gynecology and Gynecologic Oncology, and exclusively to FemSuite for use in anal (fecal) incontinence in the fields of Urology, General Surgery and GI Surgery. FemSuite will organize a subsidiary (the "Subsidiary"), to which the license will be assigned, which plans to test and market up to four products covered by the Patents (the "Patents").
